What McKesson Ventures does

McKesson Ventures is the corporate venture capital arm of McKesson Corporation (NYSE: MCK), a Fortune 15 pharmaceutical distributor and healthcare IT company. Founded in 2014 by Tom Rodgers, the firm invests in venture and growth-stage companies building innovative software and services for the healthcare and pharmaceutical industries. The fund operates with a small team (1-10 employees) based in San Francisco and deploys capital across two primary investment categories: Pharma Tech Services (data analytics, evidence generation, and commercialization platforms such as Aetion, Atropos Health, Komodo Health, BranchLab, and Prudentia Sciences) and Health-Tech & Tech Enabled Services (care delivery, telehealth, and clinical AI companies such as Aledade, IVX Health, Midi Health, Latent, and Oath Surgical).

The firm's core value proposition is its direct connection to McKesson Corporation's healthcare ecosystem, including the parent's pharmaceutical supply chain (delivering approximately 30% of America's medicines), oncology network (treating 40% of U.S. cancer patients through The US Oncology Network), and relationships with pharmacies, payors, providers, and manufacturers. Portfolio companies gain strategic introductions, domain expertise on U.S. healthcare system mechanics, and access to McKesson subsidiaries including CoverMyMeds, Biologics, and Ontada as ecosystem partners. The firm does not sell a discrete technology product; its "product" is capital plus curated ecosystem access.

McKesson Ventures generates returns through equity investments in healthcare technology startups, with realized exits including Accolade, Amwell, and Hims (IPOs), GRAIL (acquired by Illumina), Landmark (acquired by Optum), Propeller (acquired by ResMed), Xealth (acquired by Samsung Electronics), and RxLightning (acquired by McKesson). In 2025 the firm expanded into growth-stage equity investing by adding a dedicated growth equity function led by Peter Lafer, formerly a Principal at General Atlantic. Recent investment activity has concentrated in AI-enabled healthcare companies — clinical AI (Latent), pharmaceutical commercialization (BranchLab, Prudentia Sciences), and AI-powered surgical care (Oath Surgical) — alongside a unicorn-scale outcome in women's health (Midi Health, $100M Series D at $1B+ valuation in 2026).

Name

McKesson Ventures

Legal name

McKesson Corporation

Website

https://ventures.mckesson.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

McKesson Ventures is McKesson Corporation's corporate venture capital arm, investing in venture and growth-stage healthcare technology and pharma services companies. The firm provides portfolio companies with capital and strategic access to McKesson's healthcare ecosystem spanning pharmaceutical distribution, oncology, and pharmacy operations.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

Keywords

• Venture capital investing
• Healthcare technology investing
• Growth equity funding
• Pharma tech services
• Healthcare startup funding

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Investment Returns: McKesson Ventures generates returns through equity investments in healthcare technology startups, benefiting from McKesson's strategic position in the pharmaceutical supply chain and healthcare ecosystem. Returns realized through portfolio company exits via IPO or acquisition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

McKesson Ventures is the corporate venture capital arm of McKesson Corporation that invests in venture and growth-stage companies building innovative software and services for the healthcare and pharmaceutical industries. The firm provides capital, strategic guidance, and access to McKesson's extensive healthcare ecosystem, including relationships with pharmacies, payors, providers, and manufacturers. Investment focus spans two primary categories: Pharma Tech Services and Health-Tech & Tech Enabled Services.

Product overview

McKesson Ventures is a strategic venture capital firm that invests in innovative software and services companies within the healthcare and pharmaceutical industries. Rather than operating a unified product platform, McKesson Ventures functions as an investment vehicle providing capital, strategic guidance, and access to the broader McKesson healthcare ecosystem to its portfolio companies. The firm's investment focus spans two primary categories: Pharma Tech Services (including companies like Aetion, Atropos Health, BranchLab, Clinical Ink, Komodo Health, Prudentia Sciences, and Saama focused on data analytics, evidence generation, and commercialization) and Health-Tech & Tech Enabled Services (including companies like Aledade, IVX Health, Latent, Midi Health, Oath Surgical, and Reimagine Care focused on care delivery, telehealth, and clinical AI). The portfolio companies maintain their own distinct products and services independently.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment Program Equity investment program targeting venture-stage healthcare technology and services companies. Provides capital, strategic guidance, and access to McKesson's healthcare ecosystem including relationships with pharmacies, payors, providers, and manufacturers. Focus areas include data analytics, evidence generation, clinical research, and care delivery.
• Growth Equity Investment Program Equity investment program targeting growth-stage and profitable healthcare companies. Provides growth capital with strategic partnership to scale operations, enter new markets, and expand offerings. Led by Head of Growth Equity Peter Lafer.

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered strategic and core.

• GuidehousestrategicStrategic or Co-development Partner · 18 May 2026Portfolio company Atropos Health partnered with Guidehouse to jointly develop clinical decision support solutions operationalizing real-world evidence for clinical and life sciences teams.
• DoximitystrategicStrategic or Co-development Partner · 13 May 2026Portfolio company Aledade partnered with Doximity to integrate Scribe and Ask AI technologies into Aledade Assist electronic health overlay for value-based care settings.
• Samsung ElectronicsstrategicStrategic or Co-development Partner · 8 July 2025Portfolio company Xealth was acquired by Samsung Electronics to combine wearable technology with Xealth's digital health platform, bridging wellness and medical care.
• The US Oncology NetworkcoreStrategic or Co-development PartnerStrategic partnership supporting community-based specialty oncology practices through McKesson's connected network of cancer care providers.
• US Oncology Research (SCRI)coreStrategic or Co-development PartnerPartnership enabling patient enrollment in oncology clinical trials as part of McKesson's comprehensive cancer care ecosystem.
• CoverMyMedscoreStrategic or Co-development PartnerMcKesson subsidiary providing medication access solutions including electronic prior authorization, e-prescribing, and patient support programs.
• BiologicscoreStrategic or Co-development PartnerSpecialty pharmacy services supporting patients on 200+ specialty therapies as part of McKesson's comprehensive pharmacy ecosystem.
• OntadacoreStrategic or Co-development PartnerMcKesson subsidiary providing community oncology real-world data and evidence for research and clinical decision support.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• General Atlantic: Large global growth equity firm with deep healthcare investing practice. McKesson Ventures' Head of Growth Equity Peter Lafer was previously a Principal at General Atlantic, indicating talent and strategy overlap.
• Bessemer Venture Partners: Established venture capital firm with significant healthcare practice. While broader than McKesson Ventures' healthcare-exclusive focus, it competes for similar growth-stage healthcare software and services investments.

Direct peers

• CVS Health Ventures: CVC arm of CVS Health, investing in healthcare technology startups. Provides similar strategic value proposition combining capital with healthcare ecosystem access (pharmacy, insurance, providers).
• Optum Ventures: CVC arm of UnitedHealth Group's Optum, one of the largest healthcare CVCs. Invests across healthcare services, technology, and care delivery with strategic ecosystem access comparable to McKesson Ventures.
• Walgreens Boots Alliance Ventures: CVC of major pharmacy and healthcare company, investing in digital health and tech-enabled care delivery. Comparable CVC structure with retail pharmacy ecosystem access.
• LRVHealth: Healthcare-focused venture and growth equity firm investing across care delivery, technology, and services. Co-invested with McKesson Ventures in Lumata Health Series B, showing direct syndicate overlap.
• Echo Health Ventures: Strategic CVC investing in healthcare innovation, formed as a partnership between Cambia Health Solutions and Mosaic Health Solutions. Operates with similar CVC mandate focused on healthcare transformation and portfolio ecosystem support.
• Kaiser Permanente Ventures: Healthcare-focused CVC associated with Kaiser Permanente, invests in healthcare technology and services. Notably, McKesson Ventures President Dave Schulte previously led Kaiser Permanente Ventures, establishing direct personnel and strategy overlap.
• Cardinal Health Ventures: CVC arm of Cardinal Health, another top-tier pharmaceutical distributor competing directly with McKesson. Invests in healthcare technology with similar strategic rationale.
• Cencora Ventures: Corporate venture arm of Cencora (formerly AmerisourceBergen), one of the largest pharma distributors and direct competitor to McKesson. Invests in healthcare tech and pharma services with similar CVC structure and ecosystem access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mckesson-ventures
• Xx.com/MCK_Ventures
• Facebookfacebook.com/timeline

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments62 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about McKesson Ventures